IL286212A - Aav mutant having brain-targeting property - Google Patents

Aav mutant having brain-targeting property

Info

Publication number
IL286212A
IL286212A IL286212A IL28621221A IL286212A IL 286212 A IL286212 A IL 286212A IL 286212 A IL286212 A IL 286212A IL 28621221 A IL28621221 A IL 28621221A IL 286212 A IL286212 A IL 286212A
Authority
IL
Israel
Prior art keywords
brain targeting
aav mutant
closed brain
aav
mutant
Prior art date
Application number
IL286212A
Other languages
English (en)
Hebrew (he)
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Publication of IL286212A publication Critical patent/IL286212A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/015Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145Special targeting system for viral vectors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL286212A 2019-04-24 2021-09-09 Aav mutant having brain-targeting property IL286212A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019082417 2019-04-24
PCT/JP2020/017495 WO2020218419A1 (ja) 2019-04-24 2020-04-23 脳に指向性を有するaav変異体

Publications (1)

Publication Number Publication Date
IL286212A true IL286212A (en) 2021-10-31

Family

ID=72942142

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286212A IL286212A (en) 2019-04-24 2021-09-09 Aav mutant having brain-targeting property

Country Status (10)

Country Link
US (1) US12421526B2 (https=)
EP (1) EP3960755A4 (https=)
JP (1) JP7524166B2 (https=)
KR (1) KR102917057B1 (https=)
CN (1) CN113748122B (https=)
AU (1) AU2020263757B2 (https=)
BR (1) BR112021017603A2 (https=)
CA (1) CA3132447A1 (https=)
IL (1) IL286212A (https=)
WO (1) WO2020218419A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3575398A4 (en) * 2017-01-30 2020-11-11 Nippon Medical School Foundation ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
CN115960177B (zh) * 2022-10-09 2023-07-07 广州派真生物技术有限公司 腺相关病毒突变体及其应用
CN116789739B (zh) * 2022-12-08 2024-01-26 广州派真生物技术有限公司 腺相关病毒突变体及其应用
CN116284262B (zh) * 2023-02-13 2026-03-17 和元生物技术(上海)股份有限公司 高效感染ht-22细胞的腺相关病毒突变体
CN116693633B (zh) * 2023-02-21 2023-12-22 广州派真生物技术有限公司 腺相关病毒突变体及其应用
CN121569040A (zh) 2023-07-27 2026-02-24 宝生物工程株式会社 脑趋向性aav突变体
CN121816425A (zh) * 2023-09-11 2026-04-07 学校法人顺天堂 能够感染内耳的aav变体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
EP2176283B1 (en) 2007-07-14 2016-11-02 University of Iowa Research Foundation Methods and compositions for treating brain diseases
WO2010114143A1 (ja) * 2009-03-30 2010-10-07 国立大学法人岡山大学 特異的プロモーターの活性を上昇させるシステム及び該システムを保持したベクター
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
WO2013014764A1 (ja) 2011-07-27 2013-01-31 三菱電機株式会社 通信システム、通信装置および通信方法
US9938541B2 (en) 2012-12-25 2018-04-10 Takara Bio Inc. AAV variant
HK1222673A1 (zh) 2013-07-12 2017-07-07 The Children's Hospital Of Philadelphia Aav载体和用於抗aav(腺相关病毒)中和抗体的检测
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
CA2942289C (en) * 2014-03-10 2024-05-21 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
DE102014207498A1 (de) 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
US11364308B2 (en) * 2016-05-13 2022-06-21 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
EP3890017B1 (en) 2018-12-04 2025-08-13 Ningbo Sunny Opotech Co., Ltd. Photosensitive assembly, photographic module, manufacturing method for photographic assembly, and electronic device

Also Published As

Publication number Publication date
JP7524166B2 (ja) 2024-07-29
JPWO2020218419A1 (https=) 2020-10-29
BR112021017603A2 (pt) 2021-11-16
CA3132447A1 (en) 2020-10-29
AU2020263757A1 (en) 2021-10-14
KR20220004072A (ko) 2022-01-11
US12421526B2 (en) 2025-09-23
KR102917057B1 (ko) 2026-01-23
EP3960755A1 (en) 2022-03-02
EP3960755A4 (en) 2023-11-22
US20220162637A1 (en) 2022-05-26
WO2020218419A1 (ja) 2020-10-29
CN113748122B (zh) 2024-11-22
AU2020263757B2 (en) 2025-08-28
CN113748122A (zh) 2021-12-03

Similar Documents

Publication Publication Date Title
IL286212A (en) Aav mutant having brain-targeting property
IL286825A (en) Gene therapy for eye pathologies
EP3694500A4 (en) TREATMENT OF INFLAMMATORY DISORDERS
IL265528A (en) aav therapy for Huntington's disease
EP3852608A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF GLAUCOMA
IL287611A (en) Compounds and methods targeting human tau
EP3877519A4 (en) BIOSYNTHESIS OF MOGROSIDS
EP3779566C0 (en) GLASSES
EP3890603A4 (en) TRAINING FROM STRESS DISEASES
EP3717652A4 (en) GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE IIIB
EP3474903A4 (en) DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILLING
EP4051324A4 (en) Gene therapy vectors
IL281923A (en) Compositions useful for treating gm1 gangliosidosis
PL3886799T3 (pl) Kompozycje do leczenia utraty włosów
IL280343A (en) Treatment of mucopolysaccharidosis iva
EP3958878A4 (en) CONDITIONING METHODS FOR GENE THERAPY
IL263080B (en) Treatment of neurological disorders
IL289338A (en) Therapeutic interactions of leucomethylthioninium
IL285119A (en) Use of spiropidion
EP3538544A4 (en) MUTANT SUBTILASE-CYTOTOXIN-B SUB UNIT
EP3773746A4 (en) AAV6 VARIANTS
EP3918412C0 (en) GLASSES
ES1229391Y (es) Muletas emparejables por medios magnéticos
EP3853665A4 (en) ESTIMATION OF ASYMMETRIC ABERRATIONS
EP3568424C0 (en) IMPROVEMENT OF PHYSICAL PROPERTIES OF POLYURETHANES